Immuneering Corp

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Immuneering Corp advances oncology focus with promising preclinical data

Immuneering Corp (IMRX) is making significant strides in oncology with promising preclinical data and a strategic focus on developing cancer treatments with better tolerability.
While facing challenges in addressing resistance and clarifying MEK inhibitor activity, the company's unique approach and strong response profiles position them well for future growth.
Opportunities lie in advancing pipeline assets, optimizing clinical trial outcomes through informatics, and leveraging expertise in relevant cancer types for Phase 2a success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Chardan has initiated coverage of Immuneering Corp (NASDAQ: IMRX) with a Buy rating and a price target of $18. Immuneering's lead candidate, IMM-1-104, an oral MEK inhibitor, is on track for 3Q22 IND filing, with potential for data 12-18 months later.

Why This Small-Cap Stock Is Gaining More Than 10% Today?

CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in William Blair Biotech Focus Conference 2022. Participating in a panel discussion will be Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering. The discussion will include an overview of the pre-clinical data highlighting the pan-KRAS/NRAS activity of IMM-1-104.

Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will present the company's pipeline, platform, and business strategy at the Jefferies Healthcare Conference and the H.C. Wainwright Global Investment Conference, details of which are set forth below.

Immuneering Announces Participation in Upcoming Investor Conferences

IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022

Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in Citi's Biopharma VIRTUAL Co-Panel Day to discuss software, artificial intelligence and bioinformatics in drug development. Participating will be Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering.

Immuneering Announces Participation in Citi's Biopharma VIRTUAL Co-Panel Day

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in Piper Sandler's AI/ML Investor Conference to discuss software, artificial intelligence and bioinformatics in drug development. Participating will be Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering. Immuneering has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneering's disease-agnostic discovery platform enables the company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.

Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells

Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Immuneering (IMRX) This Earnings Season?

Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK pathway activating mutations including KRAS-G12D, KRAS-G12S, KRAS-G12C, NRAS-Q61R, and BRAF-V600E; IND filing is expected in Q3 2022

Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Should You Buy Immuneering (IMRX) Ahead of Earnings?

Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise

Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors

Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Rimma Steinhertz, Ph.D., PMP to the newly created position of Vice President, Project and Alliance Management, effective immediately. In this role, Dr. Steinhertz will focus on working with Immuneering's leadership team as it advances IMM-1-104 as a monotherapy into clinical trials in 2022 and working with potential future partners to advance combination approaches with IMM-1-104 in select patient populations.

Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 20, 2021.

Immuneering Added to the Nasdaq Biotechnology Index

Immuneering Announces Participation in December Investor Conferences

To highlight proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells To highlight proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells

Immuneering to Participate in Jefferies 2021 London Healthcare Conference

Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024

Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with Sotorasib in KRAS-G12C Mutant Pancreatic Cancer

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition

Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Immuneering Corporation has been selected to be added to the Russell 2000® Index effective September 20, 2021, after the close of the U.S. equity markets.

Immuneering Announces Inclusion in the Russell 2000® Index

FS KKR Capital Corp

German American Bancorp

Orange County Bancorp

Southern States Bancshares

According to the Insider Cluster Buys page, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months are Orange County Bancorp Inc. ( OBT , Financial), FS KKR Capital Corp. ( FSK , Financial), Immuneering Corp. ( IMRX , Financial), Southern States Bancshares Inc. ( SSBK , Financial) and German American Bancorp Inc. ( GABC , Financial).

5 Stocks With High Insider Buys Over Past 2 Months

Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024

Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Company management will participate in two upcoming virtual investor conferences in September 2021. At the conferences, Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will share commentary with investors around the Company's pipeline, platform and business strategy.

Immuneering to Participate in September Investor Conferences

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock, at a public offering price of $15.00 per share, for total gross proceeds of approximately $129.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering.

News for Immuneering Corp Stock (IMRX)